This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ALBO Aktienübersicht
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Albireo Pharma, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$44.15 |
| 52-Wochen-Hoch | US$45.23 |
| 52-Wochen-Tief | US$16.02 |
| Beta | 1.04 |
| 11 Monat Veränderung | -1.23% |
| 3 Monate Veränderung | 85.66% |
| 1 Jahr Veränderung | 66.73% |
| 33 Jahre Veränderung | 98.69% |
| 5 Jahre Veränderung | 28.53% |
| Veränderung seit IPO | 202.40% |
Aktuelle Nachrichten und Updates
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Aktionärsrenditen
| ALBO | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 1.2% | -3.0% | 0.9% |
| 1Y | 66.7% | 19.2% | 32.4% |
Rendite im Vergleich zur Industrie: ALBO exceeded the US Biotechs industry which returned 6.8% over the past year.
Rendite vs. Markt: ALBO exceeded the US Market which returned -9.2% over the past year.
Preisvolatilität
| ALBO volatility | |
|---|---|
| ALBO Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: ALBO's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: ALBO's weekly volatility has increased from 17% to 27% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| n/a | 130 | Ron Cooper | www.albireopharma.com |
Albireo Pharma, Inc.'s Grundlagenzusammenfassung
| ALBO grundlegende Statistiken | |
|---|---|
| Marktanteil | US$921.13m |
| Gewinn(TTM) | -US$131.14m |
| Umsatz(TTM) | US$57.39m |
16.1x
Kurs-Umsatz-Verhältnis-7.0x
Kurs-Gewinn-VerhältnisIst ALBO zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ALBO Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$57.39m |
| Kosten der Einnahmen | US$2.55m |
| Bruttogewinn | US$54.84m |
| Sonstige Ausgaben | US$185.99m |
| Umsatz | -US$131.14m |
Zuletzt gemeldete Gewinne
Sep 30, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -6.29 |
| Bruttomarge | 95.56% |
| Nettogewinnspanne | -228.51% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich ALBO auf lange Sicht entwickelt?
Historische Performance und Vergleiche